Who we are

You can scroll through this table

1993	Kirin Pharmaceuticals (China) Co., Ltd was established
1994	Gran® was launched in China
1996	Espo®was launched in China
1997	Kirin Kunpeng(China)Bio-Pharmaceutical Co.,Ltd.(KKCL)was established.
2001	Selling domesticGran® and Espo® in China
2005	Coniel®was launched in China
2008	Kyowa Hakko Pharmaceutical Technology (Shanghai) Co., Ltd（KH）was established.
2010	Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.has become a wholly-owned subsidiary which is 100% funded by the Kyowa Hakko Kirin Group
2011	As the local legal enterprise of Kyowa Hakko Kirin Co., Ltd., Kirin Kunpeng(China)Bio-Pharmaceutical Co., Ltd. was merged with Kyowa Hakko Pharmaceutical Technology(Shanghai) Co., Ltd
2012	Trade name changed to current “Kyowa Hakko Kirin（China）Pharmaceutical Co.,Ltd. ” from”Kirin kunpeng(China)Bio-Pharmaceutical Co.,Ltd.
2014	REGPARA® acquired IDL
2015	REGPARA®was launched in China
2015	Completion of construction of a new facility for the manufacture of tablets
2017	REGPARA® included in NRDL
2017	Transferring the selling right of CONIEL® in the Chinese market to Winhealth Pharma Group
2019	KKCN launched the new LOGO on July 1
2020	LUMCIEFD®(Brodalumab) acquired IDL on June
2020	NESP acquired IDL on June
2020	Kyowa Kirin Asia Pacific and Helsinn sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area.
2020	Kyowa Kirin and Winhealth Pharma Group establishes strategic cooperation on NESP
2021	Renaming the company”Kyowa Kirin China Pharmaceutical Co.,Ltd” officially